People diagnosed with neuropsychiatric disorders such as depression, anxiety, addiction or schizophrenia often have dysregulated memory, mood, pattern separation and/or reward processing. These symptoms are indicative of a disrupted function of the dentate gyrus (DG) subregion of the brain, and they improve with treatment and remission. The dysfunction of the DG is accompanied by structural maladaptations, including dysregulation of adult-generated neurons. An increasing number of studies using modern inducible approaches to manipulate new neurons show that the behavioral symptoms in animal models of neuropsychiatric disorders can be produced or exacerbated by the inhibition of DG neurogenesis. Thus, here we posit that the connection between neuropsychiatric disorders and dysregulated DG neurogenesis is beyond correlation or epiphenomenon, and that the regulation of adultgenerated DG neurogenesis merits continued and focused attention in the ongoing effort to develop novel treatments for neuropsychiatric disorders.
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Adult DG neurogenesis
Adult DG neurogenesis in laboratory animals and humans shares common features [69] [70] [71] . For example, new DG neurons occur throughout the hippocampal DG, from the dorsal (or septal) to the ventral (or temporal) DG (mouse DG shown in Fig. 1a) , albeit with distinct functional contributions along the DG longitudinal axis [72] [73] [74] [75] . Also, as with the process of embryonic neurogenesis, adult DG neurogenesis in humans and mice and rats is a process, not a timepoint, with maturing cells proceeding through "stages" (Fig. 1a) 27, 71 . In general, the proliferation, differentiation and eventual survival to maturity of new DG neurons takes 2-4 weeks in mice and rats (Fig. 1a) , but weeks longer in primates and humans, as revealed by postmortem studies 31, 76 . New DG neurons in both rodents (mice, rats) and humans do not replace existing embryonic-generated DG neurons, but rather contribute to the ongoing turnover (addition and subtraction) of newborn neurons in a restricted part of the DG (Fig. 1a) 9, 71, [77] [78] [79] [80] .
In contrast to these shared traits, most of what is known about the specific development and afferent input of new DG neurons is understood in mice and rats. Once mature, new DG neurons become glutamatergic granule neurons that receive glutamatergic input from the upstream Ent and inhibitory GABAergic feedback from DG interneurons 81 and project to the downstream hippocampal CA3 region (Box 1) 16 . In this sense, fully mature adult-generated DG neurons are indistinguishable from embyronic-generated DG granule neurons. However, as they mature, new DG neurons receive specialized inputs and outputs and dynamically express key intrinsic ion channels and neurotransmitter receptors (Fig. 1a,b) 32, 82, 83 . For example, younger new DG granule neurons receive direct innervation from mature DG granule neurons and downstream hippocampal cornus ammonis region 3 (CA3) pyramidal neurons 84 , and these inputs disappear as the new neuron matures. In addition, younger new DG granule neurons neither receive nor send feedback inhibition 81 , whereas older new DG neurons do. The location of inputs to new DG neurons is crucial for determining their influence on new neuron function 33, 35, 83 . For example, most glutamatergic inputs are on the dendritic tree of new neurons, whereas inhibitory inputs are on or near the soma (Fig. 1a) 33, 35 . These inputs form gradually over the >4 weeks that it takes for new neurons to mature (Fig. 1b) , with nonsynaptic, ambient GABA as the first input and synaptic glutamate from Ent as the last 33, 35, 83 . Taken together with the fact that new neurons have a lower threshold for firing relative to embryonic-generated neurons and that they are sensitive to activity-dependent regulation 36, [85] [86] [87] , the emerging view is that immature adult-generated DG neurons are distinct from mature adult-generated and all embryonic-generated DG neurons in that they are "young and excitable" 88 , function independently of inhibitory GABA circuits 89 and receive direct innervation from their glutamatergic "elders" 84 . In fact, some work suggests that adult-generated neurons remain functionally distinct from their embryonic-generated counterparts 90 .
Neuropsychiatric disorders and adult DG neurogenesis
It has long been known that the development of new neurons is regulated by antidepressants and drugs of abuse 41, 42 . In fact, treatments for neuropsychiatric disorders (including antidepressants, electroconvulsive treatment, antipsychotics and mood stabilizers, all of which can improve DG functional output in humans diagnosed with or animal models of neuropsychiatric disorders) act on many of the very neurotransmitter systems that regulate new neurons (Fig. 1b) 26, 91 . Such studies raise the idea that neuropsychiatric disorders are linked with fewer new DG neurons, and that treatment or remission is linked to more or a normalized number of new DG neurons.
Although this correlative relationship between new DG neurons and neuropsychiatric disorders relies on only a few human postmortem publications, there is much evidence in animal models that these disorders are linked to impaired generation or function of new DG neurons 26, 47 . New DG neurons contribute to hippocampal volume and appropriate DG function and activity, and in humans, mice and rats, these disorders are also marked by impaired hippocampal volume and/ or DG network activity ( Table 1) . For example, the relative activity between the DG and the downstream hippocampal CA1 region (Box 1) is decreased in stressed rats as compared to control rats 59 , which is
Box 1 The circuits and functional output of the hippocampal DG
The healthy hippocampal DG receives input (black lines) from the limbic system (Entorhinal cortex (Ent) via perforant path (PP), perirhinal cortex (PRH), medial septum and (not shown) contralateral DG and recurrent collaterals from hippocampal CA3) and midbrain and hindbrain modulatory regions (VTA/SN, LC, DR) 16 . Many other non-DG connections that might affect the DG indirectly are also indicated (gray lines). The DG and hippocampus are highly sensitive to stress (for example, physiological, environmental) owing to direct inputs from the hypothalamic-pituitary-adrenal axis (HPA, red lines, red shading) and putative, indirect effects from the HPA to Ent (red dotted line) [17] [18] [19] . In turn, the HPA axis is influenced by the DG in part through hippocampal, subicular and Ent projections to the HPA axis. Working in concert, these and other brain circuits contribute to functional DG output, which are shown in schematic form to represent memory, mood, pattern separation and reward. As discussed in the main text, neuropsychiatric disorders are marked by dysregulated memory, mood, pattern separation and reward processing, symptoms that are correlated with impaired DG function and/or impaired generation or function of new DG neurons which may be affected by stress (Table 1) . CA1, cornu ammon 1; CA3, cornu ammon 3; DG, dentate gyrus; DR, dorsal raphe; Ent, entorhinal cortex; HPA, hypothalamic-pituitaryadrenal; LC, locus coeruleus; NAc, nucleus accumbens septi; PFC, prefrontal cortex; PP, perforant path; PRH, perirhinal cortex; SN, substantia nigra; VTA, ventral tegmental area. 
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Debbie Maizels p e r s p e c t i v e notable, given that stress is a major precipitating factor in the exacerbation of neuropsychiatric symptoms. In animal models of bipolar disorder and schizophrenia, the stress-or novelty-induced activity of the DG is diminished 92, 93 . Additionally, humans with PTSD have decreased hippocampus and amygdala activity relative to undiagnosed, traumaexposed controls 94 . Finally, long-term cocaine users have decreased hippocampal gray matter, and abstinent heroin-dependent users have enhanced connectivity among hippocampus and reward-related brain regions relative to individuals who do not use drugs 95, 96 .
Additional support for a correlation between the presence of fewer new DG neurons and the presence or exacerbation of neuropsychiatric symptoms comes from studies in both humans and rodents in which a decreased number of new neurons or lower DG volume is normalized or improved after treatment or during remission ( Table 1) . For example, postmortem studies show that chronic antidepressant treatment restores proliferation deficits in humans with MDD 97 . Chronic treatment with the mood stabilizer lithium increases newneuron proliferation and differentiation in animal models, and the bipolar disorder medication valproate rescues aberrant DG activity and manic-like behavior in animal models 98, 99 . Furthermore, antipsychotic drugs, such as haloperidol, risperidone or clozapine, restore neurogenesis in animal models of schizophrenia, and antipsychotics can also ameliorate anxiety and restore new-neuron proliferation in an animal model of PTSD 100, 101 .
Neuropsychiatric symptoms and neurogenesis-a causative relationship? Recently, techniques have emerged that enable more focused exploration of the correlative-causative relationship of neurogenesis and neuropsychiatric disorders ( Table 2 ; see also Supplementary Table 1) . These include studies in mice and rats that ablate new neurons at a specific 'stage' of their development, manipulate the number, structure or activity of new DG neurons, or couple 'classic' new-neuron deletion techniques, such as irradiation, with behavioral investigations that reflect modern understanding of new neuron function 29, [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] . For example, by using retroviral-mediated gene transfer to express light-sensitive channels in proliferating precursors, researchers are able to control new neuron firing remotely 52 . Recently developed transgenic mouse lines also enable the targeting of new neurons 56 or of mature DG granule neurons 54 with these light-sensitive channels, and they enable inducible gene expression or deletion selectively in new neurons 53, 56, 62, 63, 65 or mature DG granule neurons 54, 55, 57 . The temporal control that researchers have over the firing of the targeted cell population in these optogenetic studies is ideal for behavioral investigations. As discussed below, most data are available for memory and mood, although studies have also confirmed a role for new DG neurons in pattern separation and reward 29, [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] .
Memory
Neuropsychiatric disorders are accompanied by memory dysfunction [20] [21] [22] . Given that recent studies support the idea that manipulation of new neurons can alter memory, it is possible that the activation of new neurons might be useful for normalizing memory dysfunction seen in neuropsychiatric disorders. For example, studies in mice have found that the ablation or inducible silencing of new or mature DG neurons impairs aspects of memory function 9, 26, 102 , with some finding impairments in memory acquisition or the learning of a new memory 52, 56 , and others finding impaired retrieval, or expression of the memory after it has been formed 52, 55 . These studies, all of which manipulate adult or embryonic-generated neurons during or before learning, suggest that enhancing neurogenesis might improve memory.
Notably, understanding the timing of neurogenesis disruption is crucial to understanding the role of new neurons in memory. For example, disruption of neurogenesis after learning has taken place impairs memory retrieval, which suggests that new neurons are needed as well for 'forgetting' 66, 67 . Given that certain neuropsychiatric disorders (PTSD, substance-related and other addictive disorders) can be considered as being marked by aberrantly strong memories, it is feasible that postlearning enhancement of neurogenesis might help to drive the forgetting of such memories.
Also relevant to neuropsychiatric disorders is recent work showing that the 'age' or stage of new DG neurons determines whether the cells are involved in functional DG output 52, 56 . For example, the stimulation of 4-week-old new DG neurons-but not of 2-week-old immature neurons or 8-week-old fully mature neurons-is required for memory retrieval 52 . This timing fits with that of new-neuron integration into DG-CA3 circuitry (Fig. 1a ) 32 , and with the concept that there is a 'critical period' during which new neurons are needed for successful memory processing 103 .
Mood disorders
With regard to mood disorders, MDD, anxiety and PTSD are strongly linked to abnormal hippocampal structure and function, and impaired mood and greater anxiety are hallmarks of these human disorders 18, 26 . Humans diagnosed with MDD often have an exacerbated or prolonged stress response and lack the typical hippocampal inhibition of the stress axis relative to individuals without depression, which again indicates that this mood disorder is linked to a dysfunctional hippocampus 18 . Notably, many correlative studies support the idea that rodents (mice and rats) exposed to chronic stress and humans diagnosed Table 1 Overview of studies correlating neurogenesis in the DG and neuropsychiatric disorders. Given that more than 2,000 publications have contributed to the correlative findings summarized here, review publications are primarily cited in Table 1 
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with MDD have decreased or dysfunctional neurogenesis, and that antidepressant treatment drives neurogenesis 47, 104 . Techniques used to ablate new neurons led to a depressive-like phenotype in mice and rats in some studies, but not others 47, 105 . These mixed messages as to the role that new neurons have in depression raises concerns that neurogenesis is an epiphenomenon, and thus not a reasonable target for treatment 106 . However, a relatively consistent conclusion from the recent studies in rodents is that new DG neurons are required for antidepressant efficacy [58] [59] [60] [61] (Table 2; Supplementary Table 1) . One clue to a potential underlying mechanism is that new neurons buffer the body's stress axis responsiveness and associated behaviors 62, 107 . For example, a loss of new neurons results in a hyperactive stress response in mice 62 . In fact, it is now hypothesized that having a decreased number of DG neurons contributes to the development of depressive-like behaviors particularly under stressful conditions, such as the psychosocial stress experienced during social defeat stress 63 . Indeed, increased DG neurogenesis in mice is sufficient to attenuate anxiety and depressive-like behavior under stress-like conditions in which the rodents are given the stress hormone corticosterone 68 . In further support of the role of new DG neurons in buffering the stress response, the positive effect on stress-induced anxiety of a neurogenic-compound-induced increase in neurogenesis is blunted by the ablation of neurogenesis 108 .
Current studies have manipulated new DG neurons or DG activity in the absence of substantial stress to address whether mood regulation is mediated by them. Notably, direct stimulation or inhibition of new DG neurons does not change anxiety behavior under basal, nonstressed conditions 56 . However, direct stimulation of mature DG granule neurons in either the dorsal or ventral DG has an innate antianxiety effect 54 . This fits with prior work showing that the dorsal DG is more linked to spatial or contextual functions, whereas the ventral DG is more linked to mood and related emotional functions 72, 74, 75 , and suggests that subregional targeting of DG activity is a potential intervention for mood disorders. This functional neuroanatomical gradient is also evident in studies in which neurogenesis is manipulated. For example, whereas reversible silencing or stimulation of new neurons in the dorsal-but not ventral-DG impairs memory acquisition and retrieval, direct stimulation of ventral DG granule cells-but not of new neurons-decreases anxiety in mice, as compared to controls 54, 56 . Thus, acute stimulation of ventral DG granule neurons could be a very useful intervention for relieving anxiety.
Pattern separation
Pattern separation is a computational term often applied to the DG to explain how cortical inputs representing spatial and contextual information converge onto the DG yet diverge into distinct outputs in the downstream CA3, a hippocampal region involved with the complementary function of pattern completion 109 . However, pattern separation is also a very relevant concept in neuropsychiatric disorders because overgeneralization (impaired pattern separation) is a barrier to symptom relief and is seen in many individuals with neuropsychiatric disorders 22 . For example, humans diagnosed with PTSD have diminished pattern separation; they generalize cues associated with a traumatic memory (crime victimization or war, for instance) to nonthreatening contexts, which thus drives fear and anxiety in these nonthreatening contexts 22 . Notably, this deficit is apparent in tests of pattern separation unrelated to the particular trauma: humans diagnosed with PTSD or related anxiety disorders perform poorly on neuropsychological tests of pattern separation 22 . By contrast, some humans diagnosed with autism spectrum disorder have enhanced pattern separation and note even slight differences in contexts or routines 110 . In PTSD, the severity of symptoms is correlated with a smaller and less active DG, as compared to healthy controls. These connections raise the possibility that the normalization of pattern separation will be accompanied by normalization of DG activity and diminished symptom severity.
Indeed, targeting new neurons in rodents can mimic these findings in humans: inhibition or ablation of new neurons impairs pattern separation, whereas stimulation of mature DG neurons or inducible enhancement of new neurons enhances pattern separation 53, 56, 57, 68, 111, 112 (Table 2  and Supplementary Table 1 ). In fact, when computational models of DG pattern separation account for the addition of new DG neurons, , a) , which eventually transitions to include synaptic GABA as well (white gradient in red bar). The last being synaptic glutamate (bottom dark blue bar, b) from Ent neurons (dark blue arrows (a)). Treatments for neuropsychiatric disorders act on many of the neurotransmitter systems that regulate new neurons (b). Ach, acetylcholine; DA, dopamine; DG, dentate gyrus; DR, dorsal raphe; Ent, entorhinal cortex (LEnt, lateral Ent; MEnt, medial Ent); GABA, gamma-aminobutyric acid; Glu, glutamate; LC, locus coeruleus; NE, norepinephrine/noradrenergic; SN, substantia nigra; VTA, ventral tegmental area.
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there is reduced overlap of activated GCs by previous memories, and thus improved pattern separation as compared to controls 27 . As with learning and memory, the 'stage' of the new neurons matters in regard to pattern separation. For example, pattern separation is reliant on young new neurons (just integrated into DG circuitry) but not on older mature new neurons or embyronic-generated DG neurons 113 . These aspects will be useful for guiding and fine-tuning potential future newneuron-based therapies for pattern separation.
Reward
With regard to reward, the ablation of new DG neurons in rats increases cocaine drug-taking and drug-seeking, as compared to controls, which suggests that decreased adult neurogenesis is a vulnerability factor in a rat model of cocaine addiction 64 (Table 2 and see also Supplementary  Table 1 ). Given work showing that environmental-enrichment-or running-induced increase in adult neurogenesis correlates with a reduction of addictive-like behaviors in rats and mice 114, 115 , it would be interesting to selectively and inducibly increase the number of new DG neurons or stimulate existing new DG neurons to test whether this would diminish drug-taking or drug-seeking in animal models of addiction. However, the only other study that has inducibly manipulated new neurons and examined reward-based hedonic behavior found the opposite result: the deletion of new DG neurons decreases a mouse's preference for a rewarding substance, in this case, sucrose 62 . Given that it is challenging to compare an animal model of cocaine addiction with oral sucrose intake, more studies are warranted to see how the manipulation of new neurons influences reward processing.
Harnessing the DG to treat neuropsychiatric disorders Given the above studies, it is intriguing to consider targeting new neurons to recalibrate dysfunctional DG activity to treat neuropsychiatric disorders. For example, in contrast to the healthy DG wherein Ent References cited target and manipulate new DG neurons or DG activity and assess a DG function (memory, mood, pattern separation, reward) relevant to neuropsychiatric disorders. Influence on DG function for memory and pattern-separation outcomes are given as enhanced, impaired or nc. Influence on DG function for mood-and reward-related are given as increased, decreased or nc. For study inclusion criteria, detailed list of results and specific figure panels that led to our conclusions in Table 2 , see Supplementary  Table 1 . Asterisk (*), altered neurogenesis post-learning; carat (^), dependent on type of conditioning (trace or delay); cross (+), cognitive flexibility; pound sign (#), only after adrenalectomy; dollar sign ($), only after, not before, memory testing; nc, not changed; self-admin, self-administration; -, not examined. p e r s p e c t i v e DG neurons and the many neuropsychiatric disorders that are linked with dysfunctional DG activity (Fig. 2e) . Many studies support the idea that the ablation or silencing of new neurons impairs aspects of memory, mood, pattern separation and the response to rewarding stimuli ( Table 2 and Supplementary Table 1) . By contrast, inducible increase in the number of new DG neurons formed, or inducible modulation of their spines, improves pattern separation and cognitive flexibility, respectively, in mice 57, 118 , and stimulation or induction of new or mature DG neurons decreases anxiety in mice 54, 68 . These studies suggest that a therapy based on the induction of new neurons has the potential to boost pattern separation and normalize learning and memory deficits (Fig. 2e) . However, the stimulation of new neurons or mature DG neurons can also inhibit DG function 54, 56 . Although the discrepancies between studies that stimulate new neurons might be due to technical issues, this urges caution when developing and employing such new-neuron-based therapies.
Because new neurons are highly sensitive to activity-dependent regulation, a related approach would be to stimulate DG activity to subsequently stimulate new neurons. Intriguingly, 'neurogenic' compounds exist that drive neurogenesis and/or improve some aspect of DG functional output in an activity-dependent manner 108, 119 . However, so far, no neurogenic compounds act directly and solely on new DG neurons. A major challenge is identifying specific receptors or proteins on new DG neurons that could be exploited for treatment purposes. This is a particularly problematic obstacle in that new DG neurons move through so many developmental stages (Fig. 1a,b) . However, the fact that new neurons develop much more slowly in primates than in rodents 76 , yet a larger proportion of hippocampal neurons turn over in humans than in rodents 31, 120 , raises the possibility that identifying a new-neuron target might be more feasible in humans.
One final way to target new neurons would be to regulate their microcircuitry to normalize dysfunctional DG activity. For example, the activation of certain DG interneurons in rodents drives sparse projections to the DG and its new neurons drive memory processes, mood regulation, pattern separation and processing of rewarding stimuli (Fig. 2a) [9] [10] [11] [12] [13] [14] [15] [16] , this functional output is disrupted in neuropsychiatric disorders, which perhaps leads to or exacerbates symptoms (Fig. 2b) . Regardless of whether the dysfunctional DG is due to changes in Ent input, the number of new DG neurons, regulation of DG activity, or some other parallel process, we propose two putative approaches for targeting new DG neurons as a way to normalize DG activity and functional output (Fig. 2c) .
The first approach-increasing Ent input to DG and thus increasing the activity of DG neurons-might be useful for disorders that have common traits of impaired learning and memory induced by hippocampal or DG dysfunction and Ent afferent dysfunction, such as MDD, PTSD and schizophrenia. In such cases, recalibration of DG functional output is feasible via the stimulation of upstream DG regions, such as deep-brain stimulation of Ent (Fig. 2d) . Indeed, it has already been shown that Ent stimulation enhances neurogenesis in mice and improves memory in both humans and mice 29, 116 . More recently, Ent stimulation is also able to activate a DG memory in a mouse model of Alzheimer's disease 117 , although the role of new neurons is not assessed in that study. It remains to be tested, however, whether this upstream stimulation and the subsequent putative enhanced new neuron number or activity will have beneficial effects on mood, pattern separation or reward (Fig. 2d) . However, given that lesioning of Ent impairs pattern separation in mice 84 , it is reasonable to hypothesize that Ent stimulation would improve pattern separation, and in turn, improve PTSD symptoms. Notably, whereas Ent-stimulation-induced memory improvement in mice acts via increased neurogenesis 29 , it remains unclear whether Ent-stimulation-induced improvement in DG function is always reliant on intact neurogenesis.
The second approach-increasing new DG neuron number or activity-builds off the unique physiology and positioning of new , d) . It remains to be tested whether this upstream stimulation and enhanced new neuron number or activity will affect mood, pattern separation or reward (indicated by question mark (?)). For (e), it has been shown in mice that direct stimulation or induction of adult neurogenesis (blue box) can improve memory, mood and pattern separation, although most of the work in this regard has shown the opposite (e.g., direct inhibition or suppression of adult neurogenesis impairs memory, mood and pattern separation). Although it has not been tested whether direct stimulation or induction of adult neurogenesis can improve reward, the converse has been shown: the suppression of adult neurogenesis enhances vulnerability in animal models of aberrant reward (e.g., addiction). DG, dentate gyrus; Ent, entorhinal cortex. p e r s p e c t i v e encoding by feedback inhibition onto mature GCs 81 , which might improve pattern separation, as has been studied indirectly 121 . In addition, the stimulation of other DG interneurons in mice promotes progenitor survival and thus adult neurogenesis 122 , which might also enhance sparse encoding and pattern separation. Indeed, the regulation of any local mechanism that drives sparse encoding and the accompanying improvement in temporal precision of activation might be a candidate for this approach 123 . Such studies are not currently feasible in humans because of the limited knowledge of new-neuron microcircuitry in humans and the invasive nature of such approaches.
Conclusions and future directions
A dysfunctional DG is considered to be an endophenotype or biological correlate of most neuropsychiatric disorders 22, 24, 59, 61, 124, 125 .
The normalization or recalibration of aberrant DG function holds potential for treatment of these disorders. New DG neurons have unique connections and physiological properties that enable them to both sense and influence DG activity. Thus, we propose that targeting new DG neurons is one way of normalizing or recalibrating a dysfunctional DG (Fig. 2e) . Another way of recalibrating a dysfunctional DG is upstream stimulation of the Ent (Fig. 2d) . We think that both of these approaches merit consideration for therapeutic normalization of DG functional output, and we predict that-in animal models at least-this normalization occurs in part via the stimulation of new DG neurons. There are numerous knowledge gaps that remain. First, specific DG output circuits in mice and rats need to be thoroughly defined, as has been done in regard to the ventral hippocampus-nucleus accumbens circuits for mood regulation 126 , because incorrect neuroanatomical or functional targeting of a circuit might impair an already disrupted network 127 . This is feasible, given the next generation of functional neuroanatomical techniques, which employ genetic promoter enhancers with cell-specific genetic-and viral-mediated, gene-transfer-induced labeling and lineage-specific transgenic lines 128, 129 . Second, a broader scope of behaviors should be tested in mice and rats, particularly as new functions of the DG are recognized 130 . It is notable how few studies cross the 'memory-mood' divide, or even consider other DG functions, such as reward. Here we have highlighted papers that examine both memory and mood 53, 54, 65 , mood and reward 62 , or memory, mood and pattern separation 56, 57 . Given that neuropsychiatric disorders are marked by a dysfunctional DG, and that the DG has a range of functional output, we encourage researchers to more frequently and pointedly cross the memory-mood divide and to explore more work with animal models of neuropsychiatric disorders. Third, additional human and postmortem work is warranted, particularly with regard to development, regulation, and most ambitiously, in vivo imaging 31, 131 . Finally, although neurogenesis does exist in the postnatal primate and specifically human DG 31, 131 , the process is presumed to take much longer than in the mouse or rat, and it is more challenging to detect cells in select stages of neurogenesis, given the limitations of current markers and the modes of assessment of new neurons in the adult human. This is relevant because postmortem human neurogenesis studies most commonly measure proliferating cells, not immature or specifically new neurons, because of technical obstacles. Should any future therapies emerge that, for example, normalize the proliferating cells that are reduced in humans diagnosed with either schizophrenia or MDD 97, 132 , a post-treatment waiting period would be warranted to assess whether indeed the therapy has any influence on DG function. Therefore, although the common model of neurogenesis and its timeline (Fig. 1a) is a simplified representation of our current knowledge, it should continue to be rigorously tested and refined, particularly in regard to human neurogenesis.
We hope that this current view of new DG neurons and neuropsychiatric disorders will drive interest in testing the postulates put forth here. These recent studies underscore that the regulation of adultgenerated DG neurogenesis merits continued and focused attention in the ongoing effort to develop novel treatments and to enable expansion of the toolkit available to treat neuropsychiatric disorders.
